{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T09:29:40Z","timestamp":1657877380732},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s13730-021-00610-0","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T13:03:03Z","timestamp":1621947783000},"page":"576-581","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nivolumab-associated glomerular endothelial injury in a patient with gastric cancer"],"prefix":"10.1007","volume":"10","author":[{"given":"Jaegi","family":"Shim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tochio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seijiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuteru","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Seta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Yahata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"issue":"4","key":"610_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559\u201374.","journal-title":"Ann Oncol"},{"issue":"3","key":"610_CR2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","volume":"90","author":"FB Cortazar","year":"2016","unstructured":"Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90(3):638\u201347.","journal-title":"Kidney Int"},{"issue":"2","key":"610_CR3","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2016.02.057","volume":"68","author":"AC Shirali","year":"2016","unstructured":"Shirali AC, Perazella MA, Gettinger S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis. 2016;68(2):287\u201391.","journal-title":"Am J Kidney Dis"},{"key":"610_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51\u201360.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"610_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45(2):160\u20139.","journal-title":"Am J Nephrol"},{"issue":"1","key":"610_CR6","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12882-016-0408-2","volume":"17","author":"K Jung","year":"2016","unstructured":"Jung K, Zeng X, Bilusic M. Nivolumab-associated acute glomerulonephritis: a case report and literature review. BMC Nephrol. 2016;17(1):188.","journal-title":"BMC Nephrol"},{"issue":"9","key":"610_CR7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2169\/internalmedicine.9814-17","volume":"57","author":"S Kishi","year":"2018","unstructured":"Kishi S, Minato M, Saijo A, Murakami N, Tamaki M, Matsuura M, et al. IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma. Intern Med. 2018;57(9):1259\u201363.","journal-title":"Intern Med"},{"issue":"1","key":"610_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","volume":"7","author":"O Mamlouk","year":"2019","unstructured":"Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019;7(1):2.","journal-title":"J Immunother Cancer"},{"key":"610_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.lungcan.2018.05.015","volume":"122","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tsuji K, Tamiya H, Shinohara T, Kuroda N, Takeuchi E. Goodpasture\u2019s disease in a patient with advanced lung cancer treated with nivolumab: an autopsy case report. Lung Cancer. 2018;122:22\u20134.","journal-title":"Lung Cancer"},{"issue":"9","key":"610_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CJI.0000000000000189","volume":"40","author":"RA Daanen","year":"2017","unstructured":"Daanen RA, Maas RJH, Koornstra RHT, Steenbergen EJ, van Herpen CML, Willemsen A. Nivolumab-associated nephrotic syndrome in a patient with renal cell carcinoma: a case report. J Immunother. 2017;40(9):345\u20138.","journal-title":"J Immunother"},{"issue":"8","key":"610_CR11","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1681\/ASN.2018050488","volume":"29","author":"MA Perazella","year":"2018","unstructured":"Perazella MA, Shirali AC. Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol. 2018;29(8):2039\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"610_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrneph.2010.171","volume":"7","author":"YH Lien","year":"2011","unstructured":"Lien YH, Lai LW. Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis. Nat Rev Nephrol. 2011;7(2):85\u201395.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"610_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/ki.2012.484","volume":"84","author":"KD Jhaveri","year":"2013","unstructured":"Jhaveri KD, Shah HH, Calderon K, Campenot ES, Radhakrishnan J. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int. 2013;84(1):34\u201344.","journal-title":"Kidney Int"},{"issue":"1","key":"610_CR14","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12882-018-1194-9","volume":"20","author":"R Yamada","year":"2019","unstructured":"Yamada R, Okawa T, Matsuo K, Suzuki M, Mori N, Mori K. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report. BMC Nephrol. 2019;20(1):14.","journal-title":"BMC Nephrol"},{"issue":"8","key":"610_CR15","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ekir.2019.06.001","volume":"4","author":"C Cassol","year":"2019","unstructured":"Cassol C, Satoskar A, Lozanski G, Rovin B, Hebert L, Nadasdy T, et al. Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int Rep. 2019;4(8):1152\u201360.","journal-title":"Kidney Int Rep"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-021-00610-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-021-00610-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-021-00610-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T09:37:00Z","timestamp":1633599420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-021-00610-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1007\/s13730-021-00610-0","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"15 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflicts of interest exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee at which the studies were conducted and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the patient in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}